X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Cadila Healthcare with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs TEVA PHARMA (Israel) - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 CADILA HEALTHCARE   TEVA PHARMA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-18
TEVA PHARMA
Dec-13
CADILA HEALTHCARE/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs5583,083-   
Low Rs3622,679-   
Sales per share (Unadj.) Rs116.31,769.6-  
Earnings per share (Unadj.) Rs17.9110.5-  
Cash flow per share (Unadj.) Rs23.1253.6-  
Dividends per share (Unadj.) Rs3.5096.77-  
Dividend yield (eoy) %0.83.4 22.7%  
Book value per share (Unadj.) Rs85.41,965.7-  
Shares outstanding (eoy) m1,023.74848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.01.6 242.8%   
Avg P/E ratio x25.726.1 98.7%  
P/CF ratio (eoy) x19.911.4 174.9%  
Price / Book Value ratio x5.41.5 367.2%  
Dividend payout %19.687.5 22.4%   
Avg Mkt Cap Rs m470,6642,443,029 19.3%   
No. of employees `00011.844.9 26.3%   
Total wages/salary Rs m18,5450-   
Avg. sales/employee Rs Th10,072.733,387.4 30.2%   
Avg. wages/employee Rs Th1,569.10-   
Avg. net profit/employee Rs Th1,547.72,085.7 74.2%   
INCOME DATA
Net Sales Rs m119,0491,500,595 7.9%  
Other income Rs m1,1320-   
Total revenues Rs m120,1811,500,595 8.0%   
Gross profit Rs m28,475410,939 6.9%  
Depreciation Rs m5,388121,295 4.4%   
Interest Rs m91129,474 3.1%   
Profit before tax Rs m23,308260,170 9.0%   
Minority Interest Rs m6281,182 53.1%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-170,787 0.0%   
Tax Rs m5,644-3,176 -177.7%   
Profit after tax Rs m18,29293,741 19.5%  
Gross profit margin %23.927.4 87.3%  
Effective tax rate %24.2-1.2 -1,983.4%   
Net profit margin %15.46.2 246.0%  
BALANCE SHEET DATA
Current assets Rs m82,0051,013,496 8.1%   
Current liabilities Rs m60,720883,855 6.9%   
Net working cap to sales %17.98.6 207.0%  
Current ratio x1.41.1 117.8%  
Inventory Days Days7391 80.5%  
Debtors Days Days9896 102.5%  
Net fixed assets Rs m83,703490,127 17.1%   
Share capital Rs m1,0243,694 27.7%   
"Free" reserves Rs m86,4210-   
Net worth Rs m87,4451,666,877 5.2%   
Long term debt Rs m25,551767,288 3.3%   
Total assets Rs m180,6533,429,341 5.3%  
Interest coverage x26.69.8 270.5%   
Debt to equity ratio x0.30.5 63.5%  
Sales to assets ratio x0.70.4 150.6%   
Return on assets %10.63.6 295.8%  
Return on equity %20.95.6 372.0%  
Return on capital %22.04.9 445.9%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m31,4410-   
CASH FLOW
From Operations Rs m9,193239,117 3.8%  
From Investments Rs m-9,737-84,729 11.5%  
From Financial Activity Rs m515-286,837 -0.2%  
Net Cashflow Rs m-29-132,449 0.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 73.87 Rs / USD

Compare CADILA HEALTHCARE With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare CADILA HEALTHCARE With: PLETHICO PHARMA  ABBOTT INDIA  FULFORD INDIA  ORCHID PHARMA LTD  SUVEN LIFE  



Today's Market

Indian Indices Trade Strong; Capital Goods Stocks Lead Gains(12:30 pm)

After opening the day in green, share markets in India have continued the momentum and are presently trading above the dotted line.

Related Views On News

CADILA HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of CADILA HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY19); Net Profit Up 274.4% (Quarterly Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

For the quarter ended June 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (up 274.4% YoY). Sales on the other hand came in at Rs 29 bn (up 29.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (4QFY18); Net Profit Up 50.4% (Quarterly Result Update)

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, CADILA HEALTHCARE has posted a net profit of Rs 6 bn (up 50.4% YoY). Sales on the other hand came in at Rs 33 bn (up 28.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Don't Panic in This Falling Market... Do This Instead(The 5 Minute Wrapup)

Oct 5, 2018

Find companies with long term durable moats, which are correcting with the current broader market sell-off.

Why You Should Be Excited, Not Sad, About the 30% Small Cap Crash(Profit Hunter)

Oct 4, 2018

Smallcaps have corrected over 30% since the beginning of the year. Find out why Richa Agarwal views this as an opportunity rather than a threat.

Taxpayers to pay salaries of CEOs/CIOs of Mutual Funds(The Honest Truth)

Oct 5, 2018

Ajit Dayal on the crisis in the market and in the mutual fund industry.

Why Are Investors In Sundaram Small Cap Fund Anxious(Outside View)

Oct 3, 2018

A small cap fund that aims to capitalise on emerging businesses and catch them young. However, its failure in keeping volatility under check is making its investors anxious.

Biggest Corrections in the Stock of Infibeam Avenues(Chart Of The Day)

Oct 3, 2018

Infibeam plunged over 70% last week. This was the second biggest single-day fall. But Infibeam witnessed such sharp falls earlier.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Oct 16, 2018 01:41 PM

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE - SANOFI INDIA COMPARISON

COMPARE CADILA HEALTHCARE WITH

MARKET STATS